Front Burner Should everybody be taking Ozempic?
48 snips
Dec 11, 2025 
Dylan Scott, a Senior Correspondent at Vox covering health, dives into the fascinating world of GLP-1 drugs like Ozempic. He discusses the World Health Organization's new recommendation for long-term obesity treatment and explains how these drugs work by altering appetite and cravings. Dylan raises intriguing points about potential benefits for treating addictions and even dementia. However, he emphasizes they aren't a one-size-fits-all solution, highlighting risks of side effects and societal pressures surrounding their use.
AI Snips
Chapters
Transcript
Episode notes
Host Shares Personal Weight-Loss Context
- Jayme Poisson shared personal weight-loss progress while introducing GLP-1s and their rising use in Canada.
- She noted up to 10% of Canadian adults use GLP-1s and WHO recently recommended them for obesity.
Why WHO Endorsed GLP-1s
- WHO recommended GLP-1s because obesity is a major global health challenge linked to millions of deaths annually.
- GLP-1 drugs produce unprecedented weight loss (15–20%) making them the most effective intervention seen so far.
How GLP-1s Quiet Food Cravings
- GLP-1s slow digestion and uniquely reach brain pathways to reduce appetite and food reward.
- People report quieter food cravings and easier resistance to ultra-processed, tempting foods.